Literature DB >> 23669732

Evaluation of the retinoids with cisplatin and vincristine in xenograft models of neuroblastoma.

Robin E Norris1, Vu T Nguyen, Peter C Adamson.   

Abstract

Retinoids have been studied for the treatment of children with neuroblastoma for >25 years. Posttransplant administration of isotretinoin is standard of care for children with high-risk neuroblastoma, whereas fenretinide remains investigational. Previous preclinical studies have evaluated the interaction of retinoids and cytotoxic agents with conflicting results. We evaluated the schedule-dependent interaction of the cytotoxic agents, vincristine and cisplatin, with the retinoids, isotretinoin and fenretinide, in xenograft models of neuroblastoma. Concomitant administration of isotretinoin or fenretinide with the cytotoxic agents did not result in any clear potentiation of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23669732      PMCID: PMC3766379          DOI: 10.1097/MPH.0b013e3182915d4a

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  38 in total

1.  Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs.

Authors:  P E Lovat; M Ranalli; F Bernassola; M Tilby; A J Malcolm; A D Pearson; M Piacentini; G Melino; C P Redfern
Journal:  Int J Cancer       Date:  2000-12-15       Impact factor: 7.396

2.  Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.

Authors:  F Formelli; L Cleris
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

3.  Response of neuroblastoma to retinoic acid in vitro and in vivo.

Authors:  C P Reynolds; D J Kane; P A Einhorn; K K Matthay; V L Crouse; J R Wilbur; S B Shurin; R C Seeger
Journal:  Prog Clin Biol Res       Date:  1991

4.  Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.

Authors:  M N Kirstein; P J Houghton; P J Cheshire; L B Richmond; A K Smith; S K Hanna; C F Stewart
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

5.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Authors:  J Thompson; E O George; C A Poquette; P J Cheshire; L B Richmond; S S de Graaf; M Ma; C F Stewart; P J Houghton
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

6.  Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials.

Authors:  Anne-Chantal Braud; Laurence Gonzague; François Bertucci; Dominique Genre; Jacques Camerlo; Gwenaelle Gravis; Anthony Goncalves; Vincent Moutardier; Frédéric Viret; Dominique Maraninchi; Patrice Viens
Journal:  Eur Cytokine Netw       Date:  2002 Jan-Mar       Impact factor: 2.737

7.  Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients.

Authors:  S Wilailak; S Dangprasert; S Srisupundit
Journal:  Int J Gynecol Cancer       Date:  2003 Sep-Oct       Impact factor: 3.437

8.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma.

Authors:  C J Thiele; C P Reynolds; M A Israel
Journal:  Nature       Date:  1985 Jan 31-Feb 6       Impact factor: 49.962

9.  Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines.

Authors:  N Sidell; A Altman; M R Haussler; R C Seeger
Journal:  Exp Cell Res       Date:  1983-10       Impact factor: 3.905

10.  Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.

Authors:  Robert Wieder; Anna C Pavlick; Margarette Bryan; Meera Hameed; Soly Baredes; Lillian Pliner; Tracie Saunders; Reju Korah
Journal:  Am J Clin Oncol       Date:  2002-10       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.